The British health services have approved a new drug in the treatment of prostate and breast cancer, under which approximately 550 men with advanced prostate cancer and 300 women with early breast cancer will receive treatment each year in England.
Amanda Pritchard, the Chief Executive of the National Health Service, confirmed that "the drug could have a significant impact on patients suffering from a range of cancers." According to the British newspaper "The Sun," trials showed that the new drug "Olaparib" can extend patients' lives by an average of six months. Breast cancer patients who underwent chemotherapy noted that the risk of tumor recurrence within four years was reduced by nearly one-third.
